Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kevin Cook headshot

Bull of the Day: DexCom (DXCM)

Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator

Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

Lilly's Cyramza Successful in Phase III First-Line NSCLC Study

Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.

Eli Lilly (LLY) Flat As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $123.50 in the latest trading session, marking no change from the prior day.

Allergan Announces FDA Acceptance of Migraine Candidate NDA

Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.

Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan's Depression Candidate Fails in Studies, Stock Down

Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.

J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression

J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales

Radius Health (RDUS) posts narrower-than-expected Q4 loss as Tymlos sales gain traction and capture additional market share.

Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates

Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line

Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft

Merck to Buy Immunotherapy Developer Immune Design for $300M

Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates

Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).

Swarup Gupta headshot

Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review

The index endured a holiday-shortened but volatile week.

Allergan Responds to Investor's Call for CEO/Chair Role Split

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.